Genetically engineered T-cells injected into 13 people with leukemia improved each person's condition, so much so that all improved to some degree, with 10 nearing or reaching remission just three months after the injection. "The fact we got a response in all 13, you can't get better than that," said Adaptimmune CEO James Noble in Abingdon, England. His company developed the treatment. A team of University of Maryland researchers took T-cells -- which fight tumor cells -- from each patient, inserted engineered genes into the cells and re-injected them in the patients.
Published in Brief: